The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. by Cui, Xiangli et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Thompson Lab Publications Biochemistry and Molecular Pharmacology 
2013-01-07 
The induction of microRNA-16 in colon cancer cells by protein 
arginine deiminase inhibition causes a p53-dependent cell cycle 
arrest. 
Xiangli Cui 
South Carolina College of Pharmacy 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/thompson 
 Part of the Biochemistry Commons, Enzymes and Coenzymes Commons, Medicinal-Pharmaceutical 
Chemistry Commons, and the Therapeutics Commons 
Repository Citation 
Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, 
Thompson PR, Hofseth LJ. (2013). The induction of microRNA-16 in colon cancer cells by protein arginine 
deiminase inhibition causes a p53-dependent cell cycle arrest.. Thompson Lab Publications. 
https://doi.org/10.1371/journal.pone.0053791. Retrieved from https://escholarship.umassmed.edu/
thompson/29 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Thompson Lab 
Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
The Induction of microRNA-16 in Colon Cancer Cells by
Protein Arginine Deiminase Inhibition Causes a p53-
Dependent Cell Cycle Arrest
Xiangli Cui1,2, Erin E. Witalison1, Alena P. Chumanevich1, Alexander A. Chumanevich1, Deepak Poudyal1,
Venkataraman Subramanian3, Aaron J. Schetter4, Curtis C. Harris4, Paul R. Thompson3, Lorne J. Hofseth1*
1Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of
America, 2 Shanxi Medical University, Shanxi, China, 3Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida, United States of America,
4 Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
Protein Arginine Deiminases (PADs) catalyze the post-translational conversion of peptidyl-Arginine to peptidyl-Citrulline in
a calcium-dependent, irreversible reaction. Evidence is emerging that PADs play a role in carcinogenesis. To determine the
cancer-associated functional implications of PADs, we designed a small molecule PAD inhibitor (called Chor-amidine or Cl-
amidine), and tested the impact of this drug on the cell cycle. Data derived from experiments in colon cancer cells indicate
that Cl-amidine causes a G1 arrest, and that this was p53-dependent. In a separate set of experiments, we found that Cl-
amidine caused a significant increase in microRNA-16 (miRNA-16), and that this increase was also p53-dependent. Because
miRNA-16 is a putative tumor suppressor miRNA, and others have found that miRNA-16 suppresses proliferation, we
hypothesized that the p53-dependent G1 arrest associated with PAD inhibition was, in turn, dependent on miRNA-16
expression. Results are consistent with this hypothesis. As well, we found the G1 arrest is at least in part due to the ability of
Cl-amidine-mediated expression of miRNA-16 to suppress its’ G1-associated targets: cyclins D1, D2, D3, E1, and cdk6. Our
study sheds light into the mechanisms by which PAD inhibition can protect against or treat colon cancer.
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Introduction
Dysregulated protein arginine deiminase (PAD) activity has
been proposed to play a role in the onset and progression of
numerous human diseases, including cancer [1]. PADs are a family
of enzymes that convert peptidyl-Arginine to peptidyl-Citrulline
(ArgR Cit) [2], a process called ‘citrullination’. Mammals encode
5 isozymes within a single evolutionarily conserved gene cluster,
which in humans is located on chromosome 1 (1p35-36) [3]. The
mammalian PAD family members, which have been designated as
PADs 1–4 and PAD6, are highly related enzymes both within and
between individual species. Elevated levels of PAD enzymes and/
or citrullinated proteins are found in multiple chronic conditions,
including colitis and colon cancer [1,4,5,6,7]. In this light, we have
developed inhibitors of PADs, and one particular inhibitor, called
Chlor-amidine (Cl-amidine), has been shown to have cytotoxicity
against cancer cell lines [8], and can be used to prevent and treat
the high colon cancer risk disease, ulcerative colitis in mice [4].
MicroRNAs (miRNA) are evolutionarily conserved, 20- to 25-
nucleotide-long, noncoding RNAs that bind to their targets
through partial complementary sequence recognition. Such
binding results in either mRNA degradation or inhibition of
translation, and therefore suppressed expression of miRNA targets
[9]. Vertebrate genomes are predicted to encode as many as 1000
unique miRNAs [10], which are thought to regulate the expression
of at least 30% of genes [11]. Therefore it is not surprising that
miRNAs have diverse biological activities, including the regulation
of cell proliferation, differentiation, and apoptosis. To this end,
miRNA-16 is a putative tumor suppressor miRNA, and is down-
regulated in a variety of human cancers, including colon cancer
[12,13,14,15,16,17,18]. One recognized function of miRNA-16 is
that it controls the cell cycle primarily through a G1 cell cycle
checkpoint [13,19,20,21,22,23,24,25,26]. Therefore, in the ab-
sence of miRNA-16, cancer cells can grow uncontrollably. With
this in mind, it has recently been demonstrated that inhibition of
PADs by Cl-amidine causes induction of p21WAF1, leading to a G1
cell cycle arrest in colon cancer cells [27]. Building off these results,
to better understand the mechanisms by which Cl-amidine causes
a G1 cell cycle arrest, we show here that in the presence of p53,
the G1 arrest caused by Cl-amidine is dependent on miRNA-16.
Methods
Cl-amidine
The synthesis of the Cl-amidine has been described previously
[28,29]. Stock concentrations of Cl-amidine were diluted in 1x
Phosphate Buffered Saline (PBS) immediately before addition to
cell culture.
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Cell culture
HCT 116 wild-type (WT) colon cancer cells were purchased
from American Type Culture Collection (ATCC; Manassas, VA).
HCT 116 p532/2 colon carcinoma cells were derived from HCT
116 WT cells, and provided by B. Vogelstein and K. Kinzler.
HCT 116 WT and p532/2 cells were cultured in McCoy’s
medium (ATCC, Manassas, VA) supplemented with 10%
Newborn Calf Serum (NBCS; GIBCO/Life Technologies, Grand
Island, NY), 2 mM glutamine (Biofluids, Rockville, MD), penicillin
(10 U/ml, Biofluids) and streptomycin (10 mg/ml, Biofluids). LS-
180 colon cancer cells, purchased from ATCC, were cultured in
Dulbecco’s Modified Eagles Medium (Hyclone, Logan, Utah)
supplemented with 10% Newborn Calf Serum (NBCS); GIBCO/
Life Technologies), 2 mM glutamine (Biofluids, Rockville, MD),
penicillin (10 U/mL, Biofluids) and streptomycin (10 mg/mL,
Biofluids).
siRNA and miRNA Transfection
For PAD4 siRNA, 36105 cells were grown in medium in 6 well
plates 1 day before transfection. Using INTERFERin siRNA
Transfection Regent (Plyplus, iLllkirch, France), the cells were
transfected with 20 nmol/L of scambled siRNA as a negative
control or PAD4 Trilencer-27 human siRNA (Origene, Rockville,
MD). After 24 h of transfection, the cells were processed for
western blot analysis to evaluate the efficacy of knock down. Cell
cycle was examined after 24 h of transfection. For anti-miR-16
and miR-16-mimic (Ambion, Austin, TX) transfection, 36105
cells were grown in medium in 6 well plates 1 day before
transfection. Using INTERFERin siRNA Transfection Reagent,
the cells were transfected with 45 nmol/L of scrambled siRNA as
negative control and anti-miR-16 or hsa-miR-16. After 24 h of
transfection, the cells were harvested in RNase free EP tubes.
Total RNA was extracted using TRIzol regent. RNA concentra-
tion was determined by Nanodrop 2000. 10 ng of total RNA was
reverse-transcribed to cDNA using TaqMan MicroRNA Reverse
Transcription kit with microRNA primers specific for hsa-miR-16
and the small nuclear protein RNU6B (U6) for normalization.
qPCR measurement of miRNA-16 and U6 expression was
performed using TaqMan MicroRNA Assays with the 7300
PCR Assay System. The relative fold change in miRNA-16 level
was used to represent the relative abundance of miRNA-16
compared with U6 expression. After 24 h of transfection with anti-
miR-16, Cl-amidine (50 mg/mL) was added and harvested for cell
cycle analysis at 0 h, 2 h, 8 h, and 24 h. Cell cycle was also
examined 24 h after transfection of the miRNA-16 mimic. All
experimental control samples were treated with an equal
concentration of a non-targeting control mimic sequence or
inhibitor negative control sequence, for use as controls for non-
sequence-specific effects in miRNA experiments. Mock-transfected
controls did not produce any significant effect on any of the
parameters analyzed.
MicroRNA expression
Global miRNA expression. HCT 116 WT cells were seeded
at 16106 cells/plate in 6 well plates in triplicate. After culture for
24 h, 25 mg/mL Cl-amidine was added into each well. Cells were
harvested at 0, 12, and 24 h separately in RNase free EP tubes.
Total RNA was extracted using TRIzol reagent (Ambion, Austin,
TX). RNA concentration was determined by the Nanodrop 2000
(NanoDrop, Wilmington, DE). 100 ng of RNA from HCT 116
WT cells was used for the nCounter miRNA Expression Assay
v1.2 (Nanostring Technologies, Seattle, WA) containing 800
miRNA’s following the manufacturer’s instructions.
miRNA-16 expression. Cells were seeded, exposed to Cl-
amidine, and harvested at the same time points as described for
global miRNA expression. For miRNA-16 detection, 10 ng of
total RNA was used to reverse-transcribe to cDNA using TaqMan
MicroRNA Reverse Transcription kit (Applied Bisystems, Foster
City, CA) according to manufacturer’s instructions and miRNA
primers specific for hsa-miRNA-16 for detection and the small
nuclear protein RNU6B (U6) for normalization (Applied Biosys-
tems). qPCR measurement of miRNA-16 and U6 expression was
performed using TaqMan miRNA Assays (Applied Bisystems) with
the 7300 PCR Assay System (Applied Bioystems). The compar-
ative threshold cycle (Ct) method was used to evaluate the relative
abundance of miR-16 compared with U6 expression (fold changes
relative to U6). All experimental treatments were carried out on
three separate occasions; each time with three replicates.
Western blot analysis
Western blots were carried out as described previously [30].
Antibodies used include anti-p53 (EMD Millipore, Rockland MA;
Mouse Monoclonal, cat# op43, 1:500), anti-p21WAF1/Cip1 (Sigma;
Rabbit Polyclonal, cat# p1486, 1:1000), anti-GAPDH (Cell
Signaling, Rabbit Monoclonal, cat#2118, 1:1000), and anti-
PAD4 (Origene; Mouse Monoclonal, cat# TA504813, 1:2000).
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit
secondary antibodies were purchased from Amersham. Both
secondary antibodies were diluted at 1:2000. Western blot signal
was detected by SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL) and developed onto
Hyperfilm (GE Life Sciences, Piscataway, NJ).
Cell cycle analysis
16106 cells were grow in 6 well plates in McCoy’s 5A medium
1 day before treatment and then treated with 50 mg/mL Cl-
amidine for corresponding times. The cells were harvested and
fixed with ice cold ethanol. After washing with 1x Phosphate
Buffered Saline (PBS) containing 0.5% Bovine Serum Albumin
twice, the cells were incubated with DNA staining solution
consisting of Propidium Iodide (PI; 10 mg/mL) and RNase
(0.1 mg/mL) for 30 min at room temperature in the dark. The
proportion of cells in each phase of the cell cycle was determined
by DNA content stained with PI using a BD-LSR-II flow-
cytometer (BD Biosciences, San Jose, CA). Data obtained were
analyzed with BD FACSDiva Software (BD Biosciences). Each
treatment was repeated on three separate occasions.
mRNA analysis
Total RNA was extracted using Trizol reagent (Invitrogen, CA).
One mg of total RNA served as template for single strand cDNA
synthesis in a reaction using oligo(dT) primers and AMV reverse
transcriptase (Promega Corp, WI) under conditions indicated by
the manufacturer. PCR of cDNA samples was performed with
samples amplified for 30 cycles of denaturation at 94uC for 30 s,
annealing at 50uC for 30 s, and extension at 72uC for 30 s with
final extension at 72uC for 10 min. The sequences for Real Time
PCR primers used were: CCND1 Forward 59-CCC TCG GTG
TCC TAC TTC AA-39, CCND1 Reverse 59-AGG AAG CGG
TCC AGG TAG TT-39; CCND2 Forward 59-TGG GGA AGT
TGA AGT GGA AC-39, CCND2 Reverse 59-ATC CAC GTC
TGT GTT GGT GA-39; CCND3 Forward 59-TGA TTT CCT
GGC CTT CAT TC-39, CCND3 Reverse 59-AGC TTC GAT
CTG CTC CTG AG-39; CCNE1 Forward 59-ATC CTC CAA
AGT TGC ACC AG-39, CCNE1 Reverse 59-AGG GGA CTT
AAA CGC CAC TT-39; CDK6 Forward 59-CCG TGG ATC
TCT GGA GTG TT-39, CDK6 Reverse 59-TCT CCT GGG
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AGT CCA ATC AC-39; GAPDH Forward 59-GAG TCA ACG
GAT TTG GTC GT-39, GAPDH Reverse 59-TTG ATT TTG
GAG GGA TCT CG-39 (Integrated DNA Technologies, Inc).
Real-time PCR (qPCR) was performed using the 7300 Real-Time
PCR Assay System (Applied Biosystems, CA) with Power SYBR
green PCR master mix (Applied Biosystems, CA) and primers for
CCND1, CCND2, CCND3, CCNE1, CDK6 and GAPDH
according to the vendor’s protocol. The CCND1, CCND2,
CCND3, CCNE1, CDK6 gene expression was normalized by
GAPDH gene expression. The fold change in the gene expression
is relative to the vector treated (1x PBS) cells harvested at 24 h.
Statistics
When more than two groups were compared, we determined
statistical differences using a one-way analysis of variance, followed
by a Scheffe’s multiple comparison test. If two groups were
compared, we used a Student’s T-test. For global miRNA analysis,
all data were imported into NSolver Analysis Software v1.0
(Nanostring Technologies) and normalized to the geometric mean
of the 100 microRNAs with the highest expression values.
Normalized data was imported into BRB-ArrayTools v4.1.0 for
analysis. Prior to analysis, data were filtered where any value less
than 10 was omitted and any microRNA missing in .50% of
samples were excluded leaving 169 microRNAs for analysis. Class
comparison test utilized Student’s T-tests to compare microRNAs
of treated vs. untreated cells. Trend tests used linear regression
modeling on ordered categorical variables of 0 h, 12 h and 24 h.
The Benjamini-Hochberg procedure was used to calculate false
discovery rates. The P value chosen for significance in this study
was 0.05.
Results
Cl-amidine causes a p53-dependent G1 arrest
To explore the functional implications of PAD inhibition, we
first asked whether the PAD inhibitor, Cl-amidine, impacts the cell
cycle. Using two independent p53 WT colon cancer cell lines, we
found that Cl-amidine caused a cell cycle arrest at the G1 phase
(Tables 1A and B; Figures S1A and S1B). Because the impact on
the G1 phase was associated with an increase in p53 and p21
(Figure S2), we tested the hypothesis that Cl-amidine caused the
G1 arrest through a p53-mediated mechanism. Results are
consistent with this hypothesis. Unlike HCT 116 WT cells, Cl-
amidine did not cause a G1 arrest in isogenic HCT 116 p532/2
cells (Table 1C; Figure S1C). To confirm that this arrest was not
due to off-target mechanisms, we knocked down PAD4 by siRNA
(Figure S3A), then examined cell cycle changes. Consistent with
the understanding that the G1 cell cycle arrest by Cl-amidine is
due at least in part to its ability to suppress PAD activity, PAD4
knockdown also caused a G1 cell cycle arrest (Table 1D;
Figure S3B) in HCT 116 cells. Cell cycle was examined 24 h
after transfection.
Cl-amidine causes a p53-dependent induction of miRNA-
16
We have previously shown that the PAD inhibitor, Cl-amidine,
stimulates apoptosis of inflammatory cells and modestly stimulates
apoptosis in HT-29 colon cancer cells [4]. As well, we confirmed
previous results from Li et al. [27] in that PAD4 knock-down and
Cl-amidine treatment caused a G1 cell-cycle arrest in a p53-
dependent manner (Table 1; Figures S1 and S2). Since miRNA’s
have emerged as key moderators of colonic cell proliferation and
apoptosis [31], we examined global miRNA expression changes in
HCT 116 colon cancer cells exposed to Cl-amidine. Table 2 shows
there was a significant positive correlation in 11 miRNAs, and
significant negative correlation in 7 miRNAs after exposure of
HCT 116 cells to Cl-amidine for 0 h, 12 h, and 24 h. Based on
the understanding that miRNA-16 is down-regulated in colon
cancer [18], and miRNA-16 was shown to be the miRNA that was
most up-regulated (significantly) by Cl-amidine (1.5 fold at 12 h; 2
fold at 24 h; Table 2), we decided to further explore the
consequences and mechanisms of Cl-amidine-mediated miRNA-
16 up-regulation. To confirm miRNA-16 up-regulation by Cl-
amidine, we repeated the experiment and examined miRNA-16
activation by qRT-PCR. Consistent with the global miRNA
analysis results, Figure 1A shows that there was increasing
miRNA-16 expression with increasing time when HCT 116 cells
were exposed to Cl-amidine, with significance being reached at
both 12 h and 24 h (p,0.05). There was also an increase in
miRNA-16 with increasing time exposed to Cl-amidine in the p53
WT LS-180 colon cancer cell line; significance being reached at
24 h (Figure 1B). The lower increase in miRNA-16 induction is
consistent with the relatively modest G1 cell cycle arrest in the LS-
180 cells (Table 1B; Figure S1B).
Because p53 enhances the post-transcriptional maturation of
miRNA-16 [32], and Cl-amidine causes an induction in p53
(Figure S2), we examined whether the induction of miRNA-16 by
Cl-amidine was p53-dependent. Figure 1C shows Cl-amidine was
unable to cause an increase in miRNA-16 in HCT 116 p532/2
cells, indicating miRNA-16 induction was indeed p53-dependent.
Table 1. Percentage of cells in G1, S and G2 following
exposure to Cl-amidine (50 mg/ml).
A. HCT 116 Cells
Time (h) G1 S G2
0 49.667.5 34.7611 14.462.9
2 55.860.7 25.664.3 15.262.8
8 58.866.4 22.765.5 17.463.7
24 78.865.3* 9.162.8** 11.464.1
B. LS-180 Cells
Time (h) G1 S G2
0 62.361.8 18.061.1 16.764.3
2 67.160.8 16.161.27 12.560.4
8 67.565.0 14.961.1 14.364.2
24 68.760.3* 15.060.3 12.160.2
C. HCT 116 p532/2 Cells
Time (h) G1 S G2
0 50.768.3 25.867.8 18.460.5
2 47.160.8 28.661.5 19.061.3
8 44.464.6 28.160.8 19.160.5
24 51.2611 22.864.3 18.560.5
D. PAD4 siRNA HCT 116 Cells
Treatment G1 S G2
scrambled siRNA control 59.261.3 18.6761.4 19.560.4
PAD4 siRNA 81.8362.2* 6.460.9** 862.3***
*, indicates significant increase in the number of cells in G1 phase.
**, indicates significant decrease in the number of cells in S phase.
***, indicates significant decrease in the number of cells in G2 phase.
doi:10.1371/journal.pone.0053791.t001
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The p53-dependent G1 arrest by Cl-amidine is regulated
by miRNA-16
Given the observation that both the G1 arrest and increase in
miRNA-16 by Cl-amidine were p53-dependent; that p53
enhances the maturation of miR-16 [32]; and that others have
shown miRNA-16 causes a G1 arrest
[13,19,20,21,22,23,24,25,26], we hypothesized that miRNA-16 is
at the crossroads of the p53-dependent G1 arrest induced by PAD
inhibition. To test this hypothesis, we knocked down miRNA-16
(Figure S3C) in HCT 116 cells, then exposed the cells to Cl-
amidine. Results shown in Table 3A and Figure S3D indeed
indicate that the G1 arrest caused by Cl-amidine in HCT 116 WT
cells is dependent on miRNA-16, because in the absence of
miRNA-16, Cl-amidine was unable to cause the cell cycle arrest.
To confirm these results, we transfected HCT 116 cells with
miRNA-16 siRNA and a miRNA-16 mimic. After incubation for
24 h with no transfection, transfection of miRNA-16 siRNA or the
miR-16 mimic, cells were harvested and cell cycle examined.
Table 3B shows the miRNA-16 mimic caused a G1 cell cycle
arrest, supporting the hypothesis that the induction of miRNA-16
by Cl-amidine is a key event that leads to a G1 arrest in colon
cancer cells with a p53 WT background. Taken together, we
conclude that the p53-dependent G1 arrest is in turn dependent
on the ability of PAD inhibition by Cl-amidine to up-regulate the
expression of miRNA-16.
Cl-amidine causes a downregulation of miRNA-16 targets
involved in a G1 arrest
We have shown that miRNA-16 is at the crossroads of the G1
arrest in colon cancer cells by Cl-amidine. It would therefore stand
to reason to examine the effects of Cl-amidine on miRNA-16
targets that are involved in a G1 cell cycle arrest. Such targets
include: cyclin D1 (CCND1) [13,19,33,34,35,36], cyclin D2
Figure 1. miRNA-16 expression changes in p53 WT colon
cancer cells after exposure to Cl-amidine. (A) HCT 116 WT cells;
(C) LS-180 cells.; (C) HCT 116 p532/2 cells. Cells were exposed to 25 mg/
mL Cl-amidine for indicated times (N= 9 plates per time point). Relative
endogenous miR-16 expression levels were detected by qRT-PCR using
Taqman primers and probes to detect mature miR-16 and the small
nuclear RNA RNU6B (U6), an internal control. Relative miR-16 expression
levels were normalized to the average value of the non-treated samples
(0 h). *, indicates significant difference from the 0 hr control.
doi:10.1371/journal.pone.0053791.g001
Table 2. miRNA expression changes with exposure to Cl-
amidine (25 mg/ml).
Correlation
coefficient
Parametric p-
value FDR* Unique id
1 0.949 0.0002625 0.0222 hsa-miRNA-16
2 20.949 0.0002625 0.0222 hsa-miRNA-453
3 0.896 0.0029125 0.0984 hsa-miRNA-19b
4 0.896 0.0029125 0.0984 hsa-miRNA-31
5 20.896 0.0029125 0.0984 hsa-miRNA-496
6 20.843 0.0077506 0.218 hsa-miRNA-484
7 20.926 0.0118115 0.285 hsa-miRNA-1283
8 0.791 0.0190648 0.293 hsa-miRNA-21
9 0.791 0.0190648 0.293 hsa-miRNA-221
10 0.791 0.0190648 0.293 hsa-miRNA-222
11 0.791 0.0190648 0.293 hsa-miRNA-331-3p
12 20.819 0.0245418 0.322 hsa-miRNA-362-3p
13 0.849 0.0281225 0.322 hsa-miRNA-128
14 0.738 0.0323966 0.322 hsa-let-7a
15 0.738 0.0323966 0.322 hsa-miRNA-103
16 0.738 0.0323966 0.322 hsa-miRNA-200b
17 20.738 0.0323966 0.322 hsa-miRNA-655
18 20.756 0.0390752 0.365 hsa-miRNA-99a
*, indicates False Discovery Rate.
doi:10.1371/journal.pone.0053791.t002
Table 3. Percentage of HCT 116 cells in G1, S and G2
following miRNA-16 knockdown and exposure to Cl-amidine
(50 mg/ml) (A) or miRNA-16 mimic transfection (B).
A. miRNA-16 siRNA + Cl-amidine (50 mg/mL)
Time (h) G1 S G2
0 64.660.96 13.660.70 15.961.10
2 64.060.83 13.660.51 16.460.46
8 63.660.97 11.060.76 15.460.46
24 60.460.56 16.560.12 17.060.91
B. miRNA-16 mimic
Treatment G1 S G2
Control 63.960.10 15.660.76 17.560.81
miR16 siRNA 65.460.56 12.360.75 18.960.35
miR16 mimic 69.260.90* 9.861.00 17.760.80
*, indicates significant increase in the number of cells in G1 phase.
doi:10.1371/journal.pone.0053791.t003
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(CCND2)[13], cyclin D3 (CCND3) [33], cyclin E1 (CCNE1)
[13,21,24,35], and cyclin-dependent kinase-6 (cdk6) [35]. In
examining the effects of Cl-amidine on these miRNA-16 targets,
we found a significant decrease in all endpoints (Figure 2). This is
consistent with the hypothesis that PAD inhibition by Cl-amidine
activates miRNA-16, which in turn, down-regulates multiple genes
known to be involved in G1 progression.
Discussion
PADs were first discovered in vertebrates in the early 1980’s
within the epidermis of newborn rats [37]. Since then, it has
become increasingly apparent that PAD activity, with resultant
protein citrullination, drives many inflammatory diseases and
cancers, including colitis and colon cancer [1,4,5,6]. Therefore, to
develop therapies based on PAD signaling to suppress or prevent
colon cancer, it is important to understand the mechanisms. We
have identified that the inhibition of the PADs by our novel small
molecule inhibitor (Cl-amidine) suppresses the high colon cancer
risk disease, ulcerative colitis, in mice [4]. Here, we have extended
these studies, and demonstrated that Cl-amidine causes a G1 cell
cycle arrest in colon cancer cells, that this effect is mediated by up-
regulating the expression of the putative colon cancer tumor
suppressor microRNA, miRNA-16; and that this only occurs in
the presence of the tumor suppressor protein, p53. Although we
have yet to show that Cl-amidine suppresses colon cancer in mice,
results here dissect the mechanisms by which PAD inhibition by
Cl-amidine will likely suppress colon cancer. Given the close
association between colon inflammation and colon cancer risk
[38,39,40,41,42], our previous study showing that Cl-amidine
suppresses colitis [4] also predicts that Cl-amidine can be used to
prevent and/or treat colon cancer. In addition to suppressing
inflammation, the present study indicates that an additional
mechanism (for suppressing colon cancer by Cl-amidine) is
through the p53 and miRNA-16 dependent G1 cell cycle arrest
in colon cancer cells. The exact reasoning for the cell cycle arrest
caused by the PAD inhibition-mediated increase in miRNA-16,
however, remains to be elucidated. Although we saw an increase
in p21WAF1 with Cl-amidine treatment (Figure S2), this does not
appear to be the sole event that causes the G1 arrest, because of
our miRNA-16 evidence (miRNA-16 ablation negates the G1
arrest by Cl-amidine: Table 3; Figures S3C and S3D). To this end,
miRNA-16 has emerged as an especially key miRNA in the G1
cell cycle checkpoint. miRNA-16 targets several cell cycle
regulators, including cyclin D1 (CCND1), cyclin D2 (CCND2),
cyclin D3 (CCND3), cyclin E1 (CCNE1), cyclin-dependent kinase-
1 (cdk1), cdk6, cdc25a, and ADP-ribosylation factor-like protein 2
(ARL2) [13,19,21,24,26,33,34,35,36,43,44]. Given their clear
roles in driving the progression of dividing cells through the G1
phase, especially cdk6, cyclin D, and cyclin E, the ability of
miRNA-16 to target such molecules is the most likely reason for
our findings (Figures 2 and 3). Another separate set of experiments
outside the scope of the current study involves the functional
implications of other miRNA’s shown to have differential
expression following exposure of HCT 116 cells to Cl-amidine
(Table 2).
Since Cl-amidine is a pan-PAD inhibitor [45], it remains to be
shown which PAD is key to the induction of a G1 cell cycle arrest.
Our finding that the down-regulation of PAD4 through siRNA
causes a comparable G1 arrest to that of Cl-amidine (Tables 1A
and 1D), indicates PAD4 is at least one of the key PAD enzymes
responsible for cell cycle progression independent of the other
PADs. Consistent with this finding is the understanding that PAD4
activity is elevated in colon adenocarcinomas [6]. However, due to
the pan-PAD activity of Cl-amidine, we cannot rule out the impact
of other PADs on cell cycle progression. This is especially true for
PADs known to be expressed in cells of epithelial/carcinoma
origin (those used in this study), including PAD1 [46], PAD2 [47]
and PAD3 [7].
Figure 2. Cl-amidine suppresses mRNA levels of miRNA-16
targets. HCT 116 cells were treated with 1x PBS (2) or 25 mg/mL Cl-
amidine (+) for 24 h., then RNA harvested for qPCR as described in
methods. The CCND1, CCND2, CCND3, CCNE1, and cdk6 gene
expression were normalized by GAPDH gene expression. *, indicates
significant difference from the control (2) (p,0.05).
doi:10.1371/journal.pone.0053791.g002
Figure 3. Model diagram generated by experiments carried out
in this manuscript. The inhibition of PADs by Cl-amidine activates
p53, which in turn activates miRNA-16. The activation of miRNA-16
causes a G1 cell cycle arrest, presumably by targeting cyclins D, E and/or
cdk6.
doi:10.1371/journal.pone.0053791.g003
Protein Arginine Deiminases and Colon Cancer
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e53791
Our finding that Cl-amidine causes an induction of p53
(Figure S2) and inhibits cell growth in a p53-dependent manner
is consistent with other groups [27,48]. The mechanisms of p53
induction by PAD inhibition, however, remain unclear. PAD4 can
regulate gene expression by catalyzing the posttranslational
citrullination of a number of Arg residues in histone substrates
[49,50]. PAD4 can be recruited to histones by its interaction with
p53 [27]. As a result, PAD4 gets recruited to the promoters of p53-
targeted genes where it citrullinates histones and represses the
transcription of p53-targeted genes. PAD4 can also citrullinate
non-histone proteins that associate with p53 and are implicated in
carcinogenesis. Notably, PAD4 can citrullinate Inhibitor of growth
protein 4 (ING4), thereby inhibiting the ING4-mediated activation
of p53 [51]. Such mechanisms support the finding that PAD
inhibition by Cl-amidine causes p53 induction. Finally, we are
exploring the possibility that p53 can be citrullinated, leading to
the generation of SDS-insoluble aggregates, similar to a number of
cancer associated p53 mutations [52]. If this is the case, the
inhibition of p53 citrullination (by Cl-amidine) would lead to
increased p53 levels by preventing this aggregation phenotype.
In conclusion, given the increasing understanding that PAD
activity (and resultant citrullination) plays a key role in chronic
diseases such as inflammatory diseases and cancer, it is important
to better understand the mechanisms. Very little is currently
known in this regard. With respect to cancer, here we have
demonstrated that miRNA-16 plays a vital role in modulating the
G1 cell cycle checkpoint induced by PAD inhibition in p53 WT
colon cancer cell lines in vitro. Although the in vivo translation
remains to be shown, these current experiments shed light into the
mechanism by which PAD inhibition by our novel PAD inhibitor,
Cl-amidine, works. Our mechanistic findings open up the
possibility that PAD inhibitors alone, or in concert with p53
and/or miRNA-16 mimics, may have efficacy in the chemopre-
vention and/or treatment of colon cancer.
Supporting Information
Figure S1 Representative flow cytometric histograms
on indicated colon cancer cell lines. (A) Histograms at
indicated time points showing Cl-amidine (50 mg/mL) induces
a G1 phase arrest in HCT 116 cells, which are p53 WT. (B)
Histograms at indicated time points showing Cl-amidine (50 mg/
mL) induces a G1 phase arrest in LS-180 cells, which are p53 WT.
(C) Histograms at indicated time points showing Cl-amidine
(50 mg/mL) does not induce a G1 phase arrest in HCT 116 p532/
2 cells, which are deficient in p53.
(TIF)
Figure S2 Cl-amidine causes an induction in p53 and
p21 in HCT 116 cells, but not in HCT 116 p532/2 cells.
Cells were exposed to indicated concentrations of Cl-amidine for
24 h, then harvested for western blot analysis. Numbers under the
bands are GAPDH-adjusted densitometry values relative to the
control group (0 mg/mL Cl-amidine).
(TIF)
Figure S3 (A, B). Knocking down PAD4 (A) causes a G1
cell cycle arrest in HCT 116 cells (B). (A) Western blot
analysis showing PAD4 knockdown with siRNA to PAD4.
Numbers under the bands are GAPDH-adjusted densitometry
values relative to the scrambled siRNA control group. (B)
Representative cell cycle plots after 24 h. transfection with either
scrambled siRNA or siRNA to PAD4. (C, D). After knocking
down miR-16 (C), Cl-amidine (50 mg/mL) does not cause a G1
cell cycle arrest in HCT 116 cells (D). (C) Quantification of
miRNA-16 expression by Q-PCR. *, indicates significant re-
duction in miRNA-16 expression at 24 h post-transfection
compared with scrambled control siRNA. Note that Cl-amidine
did not affect the efficiency of miRNA-16 knockdown. (D)
Representative flow cytometric histogrtams after 24 h. transfection
with anti-miR-16, then exposure to Cl-amidine (50 mg/mL) for
indicated time points.
(TIF)
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